In mid November the biopharma industry was shocked by the announcement from Geron that they were ending work on embryonic stem cell research and therapy. For more than 10 years the public image of all stem cell research has been equated with embryonic stem cells. Unfortunately, a fundamentally important medical and financial fact was being ignored: embryonic stem cell therapy is extremely immature. In parallel to efforts in embryonic stem cell research and development, scientists and physicians in the field of adult stem cells realized that the natural role of adult stem cells in the body is to promote healing and to act like endogenous “repair cells” and, as a result, numerous companies have entered the field of adult stem cell therapy with the goal of expanding numbers of adult stem cells for administration to patients with various conditions. In contrast to embryonic stem cells, which are extremely expensive and potentially dangerous, adult cell cells are inexpensive and have an excellent safety record when used in humans. Many studies are now showing that adult stem cells are practical, patient-applicable, therapeutics that are very close to being available for incorporation into the practice of medicine. These events signal the entrance of the field of stem cells into a new era: an era where hype and misinformation no longer triumph over economic and medical realities.
The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:
MTF therapy features exosomes and over 300 beneficial molecules
Works in synergy with our stem cells
Offers anti-inflammatory and regenerative effects
Delivered in an easy-to-administer aerosol format via the nose
To discover more about MTF and its benefits, click here
We use cookies to ensure that we give you the best experience on our website. To find out more about cookies and how we use them on this site, see our privacy policy.AcceptPrivacy Policy